Search

Displaying results 7351 - 7360 of 9714 in total
  1. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. … For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.

  2. Drug

    Acebutolol

    go.drugbank.com/drugs/DB01193
    ApprovedInvestigational

    A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors.

  3. Drug

    Zopiclone

    go.drugbank.com/drugs/DB01198
    ApprovedInvestigational

    Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors.

    Products: ZOPICLON AL 7.5, ZOPICLON 1A PHARMA 7.5MG
  4. Drug

    Fomepizole

    go.drugbank.com/drugs/DB01213
    ApprovedVet approved

    Fomepizole is a competitive inhibitor of alcohol dehydrogenase, the enzyme that catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Dantrolene

    go.drugbank.com/drugs/DB01219
    ApprovedInvestigational

    Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.

  6. Drug

    Budesonide

    go.drugbank.com/drugs/DB01222
    ApprovedInvestigational

    Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis. … [L10598] It is also available in a combination product with [formoterol].[L10619]

    Products: BUDESONID 1A PHARMA 64UG
  7. Drug

    Levacetylmethadol

    go.drugbank.com/drugs/DB01227
    ApprovedWithdrawn

    Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index
  8. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

  9. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … [A214382] While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%),[L3450] its current indications require the co-administration of ritonavir - a potent enzyme

  10. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class.